IL1B and coronary artery disorder: The same time, preclinical and clinical studies of IL-1β inhibition have shown efficacy in the treatment of several inflammatory disorders, suggesting that IL-1β may be a novel therapeutic target for anti-inflammatory therapy such as CAD or RA [67], [68].